08Jun 2017

HISTOLOGICAL GRADE, CA 125 LEVELS AND IHC EXPRESSION OF ER/ PR, HER-2/NEU, P53 AND KI 67 MARKERS IN EPITHELIAL OVARIAN NEOPLASMS: A CORRELATIVE STUDY.

  • Department of Pathology Era?s Lucknow Medical College and Hospital.
  • Department of Gynaecology, Era?s Lucknow Medical College and Hospital.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Introduction:- Ovarian carcinoma accounts for a significant number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women. [1]. Incidence rates are higher in developed than developing countries. A female's risk at birth of having ovarian tumor sometime in her life is 6-7%. [2] In most of the population-based cancer registries in India, ovarian cancer is the third leading site of cancer among women, trailing behind cervix and breast cancer. The age-adjusted incidence rates of ovarian cancer vary between 5.4 and 8.0/100,000 population in different parts of the country. [2] Methodology:- The present study was undertaken with aim to correlate serum CA-125 levels and IHC expression of ER/PR, HER2/neu, p53 and Ki67 markers with various histological types and grades of ovarian neoplasms and their role in prognosis. Prospective histologically diagnosed epithelial ovarian neoplasm reported at Era?s Lucknow Medical College & Hospital and other collaborating hospitals consenting to participate in this study.The blood samples were used for estimating serum CA-125 levels. Ovarian biopsy/excised tumors: The ovarian tumors were used for histopathological and immune-pathological studies. Any case which have any other associated malignancy even gynecological malignancies besides ovarian cancer in present or past or any case other than epithelial ovarian neoplasm of ovary were excluded from the study. Results:- There was significant higher expression of ER and PR in serous ovarian neoplasm and among malignant cases with grade 3 tumors without any significant association with stage and grade. With increasing histopathological grade, an increase in mean serum CA-125 levels was observed but it was not significant statistically (p=0.088). Proportional differences in HER2/neu expression of cases with different clinical stages was not found to be statistically significant (p=0.443). Proportional difference in p53 expression and score in patients of different histological type was not found to be statistically significant (p=0.068). Proportional difference in Ki67 expression in patients of different histological type was found to be statistically significant (p=0.048). On follow up of serum CA-125 out of seven cases, in five cases serum CA-125 level returned to normal (<35 U/ml). However in 2 cases (both of stage IV) serum CA-125 levels were 96 U/ml and 74 U/ml respectively. Conclusion:- Although ER PR and Her 2,p53 were higher in grade 3 tumors no significant association was seen with staging.ki67 showed a statistically significant association with staging. The follow yielded normalized CA-125 levels in 5 out of 7 cases post surgery.

  1. Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2010; 21 (Supplement 5): v23?v30.
  2. Basu P, De P, Mandal S, Ray K, Biswas J. Study of 'patterns of care' of ovarian cancer patients in a specialized cancer institute in Kolkata, Eastern India. Indian J Cancer 2009;46:28-33.
  3. Sylvia MT, Kumar S, Dasari P. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables. Indian J Pathol Microbiol 2012;55:33-7.
  4. Piek JM, van Diest PJ, Verheijen RH. Ovarian carcinogenesis: An alternative hypothesis. Adv Exp Med Biol 2008;622:79-87.
  5. Levesque MA, Katsaros D, Zola P et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer. 1995; 75: 1327-38.
  6. Siegel R,?Naishadham D,?Jemal A. Cancer statistics, 2012. CA Cancer J Clin.2012 Jan-Feb;62(1):10-29.
  7. Silva EG, Lopez PR, Atkinson EN, Fente CA. A New Approach for Identifying Patients With Ovarian Epithelial Neoplasms Based on High-Resolution Mass Spectrometry. Am J Clin Pathol. 2010; 134: 903-909.
  8. Buchynska LG, Iurchenko NP, Grinkevych VM, Nesina IP, Chekhun SV, Svintsitsky VS. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers. Exp Oncol 2009;31:48-51.
  9. Hall PA, Levison DA. Review: Assessment of cell proliferation in histological material. J Clin Pathol 1990;43:184-92
  10. Gursan N, Sipal S, Calik M, Gundogdu C. P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms. Eurasian J Med 2009;41:10-4
  11. Chan WY, Cheung KK, Schorge JO et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol. 2000; 156: 409-17.
  12. Jha R,Karki S. Histological?pattern?of?ovarian tumors?and their?age distribution. Nepal Med Coll J.?2008 Jun;10(2):81-5.
  13. Cai KQ, Albarracin C, Rosen D, Zhong R, Zheng W, Luthra R, et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Human Pathology. 2004; 35: 552-9.
  14. Bosse K, Rhiem K, Wappenschmidt B, et al. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gynecol Oncol. 2006; 103: 1077-1082.
  15. Romagnolo C, Trivella G, Bonacina M, et al. Preoperative diagnosis of 221 consecutive ovarian masses: scoring system and expert evaluation. Eur J Gynaecol Oncol. 2006; 27: 487-489.
  16. Benjapibal M, Neungton C. Pre-operative prediction of serum CA125 level in women with ovarian masses. J Med Assoc Thai. 2007; 90: 1986-1991.
  17. Kalluri M, Judson MA. Sarcoidosis associated with an elevated serum CA 125 level: description of a case and a review of the literature. Am J Med Sci. 2007; 334: 441-443.
  18. Robby, Multter, Prat, Bently, Russel, Anderson. Robby?s Pathology of female reproductive Tract 2nd ed.2009;p.601-686.
  19. Lindgren PR, Cajander S, Backstrom T, et al. Estrogen and progesterone receptors in ovarian epithelial tumors. Molecular and Cellular Endocrinology. 2004; 221: 97?104.
  20. Hellstr?m I, Goodman G, Pullman J, Yang Y, Hellstr?m KE. Overexpression of HER-2 in ovarian carcinomas.Cancer Res. March 3, 2001; 61:
  21. Giurgea LN, Ungureanu C, Mihailovici MS. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors. Rom J Morphol Embryol. 2012; 53(4):967?973.
  22. Eisenhauer EL, Salani R, Copeland LJ, Di Saia PJ and Creasman WT (Eds.). Epithelial ovarian cancer in: Clinical Gynaecological Oncology 8th Ed. Elsevier. 2012;Pages 285-328.
  23. Chen VW1,?Ruiz B,?Killeen JL,?Cot? TR,?Wu XC,?Correa CN. Pathology and classification of ovarian tumors. 2003 May 15; 97(10 Suppl): 2631-42.
  24. Syriac S, Ough F, Mhawech-Fauceglia P Farghaly S (Ed.). Intech, Croatia. Borderline and Malignant Surface Epithelial ? Stromal Tumors of the Ovary In: Ovarian Cancer ? Clinical and Therapeutic Perspectives. 2012; pp. 55-85.
  25. Tavassoli FA, Devillee P (Eds.). WHO Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organisation. 2003; pp. 113-129.
  26. Clarke BA, Gilks B. Ovarian Carcinoma: Recent Developments in Classification of Tumour Histological Subtype. Can.J Pathol. 2011; 33-42.
  27. The World Health Organization Histological Typing of Breast Tumors-Second Edition. The World Health Organization. Am J Clin Pathol 78: 806-816
  28. Ovary and primary peritoneal carcinoma. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds.?AJCC Cancer Staging Manual. 7th?ed. New York, NY: Springer-Verlag; 2010:493-506.
  29. Pecorelli S, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO annual report on the results of treatment in gynaecological cancer.?J Epidemiol Biostat. 1998;3:75-102.
  30. Doyle EM,?Foley M,?Kelehan P,?Mooney EE. Histological grading of epithelial ovarian carcinomas. J Obstet Gynaecol.2007; 27(1): 71-4.
  31. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.?Adv Anat Pathol. 2009; 16: 267-82.
  32. McCluggage WG. The pathology of and controversial aspects of ovarian borderline tumours.?Curr Opin Oncol. 2010; 22: 462-72.
  33. Lee Y, Medeiros F, Mindelberger D,?et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer.?Adv Anat Pathol.?2006; 13: 1?7.
  34. Kindelberger DW, Lee Y, Miron A,?et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship.?Am J Surg Pathol.?2007; 31: 161?9.
  35. Herrington CS, McCluggage WG. The emerging role of the distal fallopian tube and p53 in pelvic serous carcinogenesis.?J Pathol.?2010; 220: 5-6.
  36. Wilkinson N, McCluggage WG.?Data sets for the histopathological reporting of neoplasms of the ovaries and fallopian tubes and primary carcinomas of the peritoneum. Royal College of Pathologists. 2010.
  37. Malpica A, Deavers MT, Lu K,?et al. Grading ovarian serous carcinoma using a two tier system.?Am J Surg Pathol. 2004; 28: 496-504.
  38. Malpica A, Deavers MT, Tornos C,?et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma.?Am J Surg Pathol.?2007; 31: 1168-74.
  39. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. ?2011; 43: 420?32.
  40. McCluggage WG. Ten Problematical Issues Identified by Pathology Review for Multidisciplinary Gynaecological Oncology Meetings. J Clin Pathol.?2012;65(4):293-301.
  41. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis; a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to ?pseudomyxoma peritonei?. Am J Surg Pathol. 1995; 19: 1390-1408.
  42. Pelkey TJ, Frierson HF, Mills SE, Stoler MH. The diagnostic utility of inhibin staining in ovarian neoplasms. Int J Gynecol Pathol. 1998;17:97-105.
  43. Zhao C, Bratthauer GL, Barner R, Vang R. Diagnostic utility of WT1 immunostianing in ovarian Sertoli cell tumor. Am J Surg Pathol. 2007; 31: 1378-1386.
  44. Cho SB, Park CM, Park SW, Kim SH, Kim KA, Cha SH, Chung IJ, Kim YW, Yoon YK, Kim JS. Malignant mixed mullerian tumor of the ovary: imaging findings. Eur Radiol. 2001; 11: 1147-1150.
  45. Anglesio MS, carey MS, Kobel M, Mackay H, Huntsman DG; Vancouver Ovarian Clear Cell Symposium Speakers. Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium. June 24th, 2010. Gynecol Oncol. 2011; 121: 407-415.
  46. Pooja S Naik1, Sanjay Deshmukh1, Siddhi Gaurish Sinai Khandeparkar1, Avinash Joshi1, Shridhar Babanagare1, Jyostna Potdar1, Neelesh Sharad Risbud. Epithelial ovarian tumors: Clinicopathological correlation and immunohistochemical study. Cancer ;2016? (4)?: 178-183
  47. Young RH, Gersell DJ, Roth LM, Scully RE. Ovarian metastases from cervical carcinomas other than pure adenocarcinomas. A report of 12 cases. Cancer 1993; 71: 407-418.
  48. Rutgers JL, Scully RE. Ovarian mixed-epithelial papillary cystadenomas of borderline malignancy of mullerian type, a clinicopathologic analysis. Cancer. 1988; 61: 546-554.

[Rekha Verma, Parul Gupta, Neema Tiwari, Nirupma Lal, H. P. Gupta and A. N. Srivastava. (2017); HISTOLOGICAL GRADE, CA 125 LEVELS AND IHC EXPRESSION OF ER/ PR, HER-2/NEU, P53 AND KI 67 MARKERS IN EPITHELIAL OVARIAN NEOPLASMS: A CORRELATIVE STUDY. Int. J. of Adv. Res. 5 (Jun). 235-254] (ISSN 2320-5407). www.journalijar.com

Dr Parul Gupta
Dr. Parul Gupta, Associate Professor, Department Of Pathology, Era’s Lucknow Medical College and Hospital ,Lucknow.

DOI:

Article DOI: 10.21474/IJAR01/4404      
DOI URL: http://dx.doi.org/10.21474/IJAR01/4404

Download Full Paper

Download PDF No. of Downloads: 115 | No. of Views: 289